



US005466670A

# United States Patent [19]

[11] Patent Number: **5,466,670**

Dunger et al.

[45] Date of Patent: **Nov. 14, 1995**

[54] **USE OF IGF-1**

[75] Inventors: **David B. Dunger**, Oxford; **Martin O. Savage**; **Peter H. Sönksen**, both of London, all of Great Britain

[73] Assignee: **PHARMACIA AB**, Sweden

[21] Appl. No.: **175,404**

[22] PCT Filed: **May 14, 1993**

[86] PCT No.: **PCT/SE93/00425**

§ 371 Date: **Feb. 1, 1994**

§ 102(e) Date: **Feb. 1, 1994**

[87] PCT Pub. No.: **WO93/23071**

PCT Pub. Date: **Nov. 25, 1993**

[30] **Foreign Application Priority Data**

May 19, 1992 [SE] Sweden ..... 9201573

[51] Int. Cl.<sup>6</sup> ..... **A61K 38/05**; A61K 38/06; C07K 5/00

[52] U.S. Cl. .... **514/12**

[58] Field of Search ..... 514/12

[56] **References Cited**

**FOREIGN PATENT DOCUMENTS**

- 0123228A2 10/1984 European Pat. Off. .
- 0308386A1 3/1989 European Pat. Off. .
- 0331630A1 9/1989 European Pat. Off. .
- 218811 7/1991 New Zealand .
- WO91/03253 3/1991 WIPO .

**OTHER PUBLICATIONS**

Diabetologia, vol. 34, 1991, E. J. Schoenle, et al., "Recombinant human insulin-like growth factor I (rhIGF I) reduced hyperglycaemia in patients with extreme insulin resistance" pp. 675-679.

Trends in Endocrinology and Metabolism, Volume, May 1990 (6), E. Rudolf Froesch, et al., "Therapeutic Potential of Insulinlike Growth Factor I" pp. 254-260.

Diabetes, vol. 40, Apr. 1991, Luciano Rossetti, et al., "Metabolic Effects of IGF-I in Diabetic Rats" pp. 444-448.

Chemical Abstracts, vol. 114, No. 114, 15 Apr. 1991 (15.Apr.1991), (Columbus, Ohio, USA), Jacob, Ralph J., et al., "Metabolic effects of IGF-I and insulin in spontaneously diabetic BB/w rats" p. 109, The Abstract No. 136379k.

Amiel, S. A. et al., (1986) N. Engl. J. Med. 315, 215-219, Impaired insulin action in puberty.

Guler, H. P. et al. (1987) N. Engl. J. Med. 317, 137-140 Short term metabolic effects of recombinant human insulin.

*Primary Examiner*—Jill Warden

*Assistant Examiner*—Benet Prickril

*Attorney, Agent, or Firm*—Pollock, Vande Sande & Priddy

[57] **ABSTRACT**

The invention relates to the use of IGF-1 for the manufacture of a medicament for treatment of Type 1 diabetes mellitus. the medicament comprising a subcutaneous dose not greater than needed to achieve an IGF-1 serum level characteristic for healthy individuals i.e. a physiological replacement of serum IGF-1. This treatment would be especially valuable for the treatment of children or adolescents with Type 1 diabetes mellitus and could lead to improvements in their pubertal growth.

**13 Claims, 6 Drawing Sheets**